- Senate passes Drug Quality and Security Act
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
WOODCLIFF LAKE, N.J. The Food and Drug Administration has accepted for review a regulatory approval application for a patch made by Eisai to treat Alzheimer’s disease, the drug maker said Friday.
The agency will review a patch formulation of Aricept (donepezil hydrochloride), a weekly patch for treating mild, moderate and severe stages of the disease. The drug already is available in tablet form.
If the patch is approved, Eisai will have marketing rights in the United States and promote the patch under a partnership with Pfizer.